Mostra i principali dati dell'item
Immune checkpoint inhibitor-induced musculoskeletal manifestations
dc.creator | Angelopoulou F., Bogdanos D., Dimitroulas T., Sakkas L., Daoussis D. | en |
dc.date.accessioned | 2023-01-31T07:31:51Z | |
dc.date.available | 2023-01-31T07:31:51Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1007/s00296-020-04665-7 | |
dc.identifier.issn | 01728172 | |
dc.identifier.uri | http://hdl.handle.net/11615/70620 | |
dc.description.abstract | Immune checkpoint inhibitors (ICI) associate with a wide range of immune-related adverse events (Ir-AE), including musculoskeletal manifestations. We aimed at identifying all studies reporting musculoskeletal Ir-AE. An electronic (Medline, Scopus and Web of Science) search was performed using two sets of key words. The first set consisted of: arthritis, musculoskeletal, polymyalgia rheumatica and myositis. The second set consisted of: anti-PD-1, anti-PD-L1, anti-CTLA-4, ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, avelumab and durvalumab. We identified 3 prospective studies, 17 retrospective studies and 4 case series reporting 363 patients in total. Combined data from all three prospective studies provide a prevalence rate of 6.13%. Most patients were males (59.68%) and the vast majority (73%) were on programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors. Most studies report a median time of ≤ 12 weeks from first ICI administration to symptom onset. The main clinical phenotypes reported were: (a) inflammatory arthritis (57.57%), (b) myositis (14.04%) and (c) polymyalgia rheumatica (PMR) (12.12%). A total of 256 patients required steroids (70.52%) and 67 patients (18.45%) were treated with DMARDs. Positive auto-antibodies and family history of any autoimmune disease were present in 18.48% and 19.04% of cases, respectively. Only a few patients (19%) had to discontinue treatment due to musculoskeletal Ir-AE. Two prospective studies show that significantly more patients with musculoskeletal Ir-AE exhibit a favorable oncologic response compared to patients not exhibiting such manifestations whereas retrospective studies show that 77.22% of patients with musculoskeletal Ir-AE have a good tumor response. One out of 15 patients treated with ICI will develop musculoskeletal Ir-AE; in most cases the severity of these manifestations is mild/moderate and usually ICI may be continued. Rheumatologists should familiarize with this new clinical entity and develop relevant therapeutic algorithms. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. | en |
dc.language.iso | en | en |
dc.source | Rheumatology International | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088835033&doi=10.1007%2fs00296-020-04665-7&partnerID=40&md5=bad8b631451cda6afbf88f957fbc2464 | |
dc.subject | atezolizumab | en |
dc.subject | autoantibody | en |
dc.subject | avelumab | en |
dc.subject | durvalumab | en |
dc.subject | immune checkpoint inhibitor | en |
dc.subject | ipilimumab | en |
dc.subject | nivolumab | en |
dc.subject | pembrolizumab | en |
dc.subject | ticilimumab | en |
dc.subject | arthritis | en |
dc.subject | autoimmune disease | en |
dc.subject | drug induced disease | en |
dc.subject | drug withdrawal | en |
dc.subject | family history | en |
dc.subject | human | en |
dc.subject | immunotherapy | en |
dc.subject | musculoskeletal disease | en |
dc.subject | myositis | en |
dc.subject | phenotype | en |
dc.subject | prevalence | en |
dc.subject | priority journal | en |
dc.subject | prospective study | en |
dc.subject | retrospective study | en |
dc.subject | Review | en |
dc.subject | rheumatic polymyalgia | en |
dc.subject | symptom | en |
dc.subject | time | en |
dc.subject | treatment outcome | en |
dc.subject | treatment response | en |
dc.subject | adverse event | en |
dc.subject | female | en |
dc.subject | immunosuppressive treatment | en |
dc.subject | male | en |
dc.subject | myositis | en |
dc.subject | rheumatic polymyalgia | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | Arthritis, Rheumatoid | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Immune Checkpoint Inhibitors | en |
dc.subject | Immunosuppression | en |
dc.subject | Male | en |
dc.subject | Myositis | en |
dc.subject | Polymyalgia Rheumatica | en |
dc.subject | Prevalence | en |
dc.subject | Springer Science and Business Media Deutschland GmbH | en |
dc.title | Immune checkpoint inhibitor-induced musculoskeletal manifestations | en |
dc.type | other | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |